

Pharmacogenomics and Companion Diagnostics

Effective Date: 03/26/2025

Revision Date: 09/26/2024

Review Date: 02/29/2024

Policy Number: HUM-0533-054

Line of Business: Commercial



Medical Coverage Policy

Table of Contents

[Related Medical/Pharmacy Coverage Policies](#)

[Coverage Determination](#)

[Coding Information](#)

[Description](#)

[Coverage Limitations](#)

[References](#)

[Change Summary](#)

Disclaimer

State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. Refer to the [CMS website](#). The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Related Medical/Pharmacy Coverage Policies

[Comprehensive Genomic Profiling and Genetic Testing for Solid Tumors](#) [Genetic Testing](#)

[Genetic Testing for Hereditary Breast, Ovarian, Pancreatic and Prostate Cancer](#)

[Genetic Testing for Hereditary Colorectal and Uterine Cancer](#)

[Homologous Recombination Repair Testing and Liquid Biopsy for Prostate Cancer](#)

[Pharmacogenomics – Cytochrome P450 Polymorphisms and VKORC1](#)

[Pharmacogenomics – Noncancer Indications](#)

[Tecelra \(afamitresgene autoleucel\)](#)

Alecensa (alectinib)

Alunbrig (brigatinib)

Augtyro (repotrectinib)

Avastin (bevacizumab)

Balversa (erdafitinib)

Elahere (mirvetuximab soravtansine-gynx)
Erbix (cetuximab)
Faslodex (fulvestrant)
Gavreto (pralsetinib)
Jemperli (dostarlimab-gxly)
Keytruda (pembrolizumab)
Kimmtrak (tebentafusp-tebn)
Krazati (adagrasib)
Libtayo (cemiplimab-rwlc)
Lorbrena (lorlatinib)
Lumakras (sotorasib)
Lynparza (olaparib)
Lytgobi (futibatinib)
Opdivo (nivolumab)
Pemazyre (pemigatinib)
Piqray (alpelisib)
Retevmo (selpercatinib)
Roctavian (valoctocogene roxaparvovec-rvox)
Rozlytrek (entrectinib)
Rubraca (rucaparib)
Tubrexa (capmatinib)
Talzenna (talazoparib)
Tazverik (tazemetostat)
Tecentriq (atezolizumab)
Tepmetko (tepotinib)
Truseltiq (infigratinib) Truqap
(capivasertib)
Vectibix (panitumumab)
Vitrakvi (larotrectinib)
Xalkori (crizotinib) Yervoy
(ipilimumab) Zykadia
(ceritinib)

Description

Pharmacogenomics and companion diagnostics tests are laboratory studies that use an individual's unique genetic makeup to help determine response to a specific medication. Companion diagnostics differ from pharmacogenomics testing because they are co-developed with a specific drug to help evaluate response or nonresponse to the drug. Companion diagnostics are often approved by the US Food & Drug Administration (FDA) corresponding with a specific pharmacotherapy. Both types of tests are used to guide management for cancers (eg, non-small cell lung cancer [NSCLC], breast, colorectal cancer [CRC]) and in noncancer indications.

Multigene (or expanded) panels analyze a broad set of genes simultaneously (as opposed to single gene testing that searches for variants in one specific gene) and have been proposed to evaluate the DNA of an individual with a personal and/or family history of more than one hereditary condition or syndrome. Panels often include medically actionable genes but may also include those with unclear medical management.

Coverage Determination

Any state mandates for pharmacogenomics and companion diagnostics testing take precedence over this medical coverage policy.

Genetic testing may be excluded by certificate. Please consult the member's individual certificate regarding plan coverage.

Apply General Criteria for Genetic and Pharmacogenomics Tests when disease- or gene-specific criteria are not available on a medical coverage policy. For information regarding General Criteria for Genetic and Pharmacogenomics Tests, please refer to [Genetic Testing](#) Medical Coverage Policy.

Adeno-Associated Virus Serotype 5 (AAV5) Antibody Testing

Humana members may be eligible under the Plan for **AAV5 antibody testing (eg, AAV5 DetectCDx)** when the following criteria are met:

- Individual diagnosed with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL); **AND**
- Testing performed using an FDA-approved test (**AAV5 DetectCDx**) prior to initiation of treatment with valoctocogene roxaparvovec-rvox (Roctavian)

ALK Mutation Testing

Humana members may be eligible under the Plan for **ALK mutation testing (eg, VENTANA ALK [D5F3] CDx Assay)** when the following criteria are met:

- Individual diagnosed with advanced, recurrent or metastatic NSCLC; **AND**
- Testing performed prior to initiation of treatment with alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), crizotinib (Xalkori) or lorlatinib (Lorbrena)

BRCA COMPANION DIAGNOSTIC TEST

Humana members may be eligible under the Plan for **BRCA companion diagnostic testing (eg, BRCAAnalysis CDx)** when the following criteria are met:

Breast Cancer

- Individual diagnosed with locally advanced or metastatic *HER2*-negative breast cancer; **AND**
 - Testing performed prior to initiation of treatment with talazoparib (Talzenna); **OR**
- Individual diagnosed with high-risk early onset, recurrent or metastatic *HER2*-negative breast cancer; **AND**
 - Treated with prior chemotherapy and/or endocrine therapy; **AND**
 - Testing performed using an FDA-approved test (**BRACAnalysis CDx**) prior to initiation of treatment with olaparib (Lynparza)

Ovarian, Fallopian Tube or Primary Peritoneal Cancer

- Individual diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer; **AND**
- Individual in a complete or partial response to platinum-based chemotherapy; **AND**
 - Testing performed using an FDA-approved test prior to initiation of maintenance treatment with olaparib (Lynparza); **OR**
 - Testing performed prior to initiation of maintenance treatment with rucaparib (Rubraca)

Pancreatic Cancer

- Individual diagnosed with metastatic pancreatic cancer; **AND**
- Treated with first-line platinum-based chemotherapy regimen for at least 16 weeks without cancer progression; **AND**
- Testing performed prior to initiation of treatment with olaparib (Lynparza)

For information regarding **germline *BRCA1* and *BRCA2* susceptibility testing for breast, ovarian and pancreatic cancer**, please refer to [Genetic Testing for Hereditary Breast, Ovarian, Pancreatic and Prostate Cancer](#) Medical Coverage Policy.

***EZH2* Mutation Test**

Humana members may be eligible under the plan for ***EZH2* mutation testing (81236, 81237)** using an FDA-approved test (**cobas *EZH2* Mutation Test**) to predict benefit from tazemetostat (Tazverik) for an individual diagnosed with follicular lymphoma.

FGFR MUTATION TEST

Humana members may be eligible under the Plan for **FGFR mutation testing (eg, theascreen FGFR [0154U]) (FGFR2 and FGFR3 genes)** when the following criteria are met:

Cholangiocarcinoma

- Individual diagnosed with unresectable locally advanced or metastatic cholangiocarcinoma, received prior treatment; **AND**
- Testing performed using an FDA-approved test (**FoundationOne CDx [0037U]**) prior to initiation of treatment with infiratinib (Truseltiq) or pemigatinib (Pemazyre)

Intrahepatic Cholangiocarcinoma

- Individual diagnosed with unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma and has received prior treatment; **AND**
- Testing performed prior to initiation of treatment with futibatinib (Lytgobi)

Urothelial Cancer

- Individual diagnosed with advanced or metastatic urothelial cancer that has progressed on at least 1 line of prior platinum-containing chemotherapy; **AND**
- Testing performed prior to initiation of treatment with erdafitinib (Balversa)

Folate Receptor Alpha Test

Humana members may be eligible under the Plan for **Folate Receptor Alpha (FR α) testing (eg, Ventana FOLR1)** when the following criteria are met:

- Individual diagnosed with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer; **AND**
- Individual has received at least 1 to 3 prior systemic treatment regimens; **AND**
- Testing performed prior to initiation of treatment with mirvetuximab soravtansine-gynx (Elahere)

Homologous Recombination Deficiency (HRD) Test

Humana members may be eligible under the Plan for **HRD testing** when the following criteria are met:

- Testing performed using an FDA-approved test (**MyChoice CDx [0172U]**) for the management of advanced, persistent or recurrent platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer; **AND**

- Prior to the initiation of combination treatment with bevacizumab (Avastin) and olaparib (Lynparza)

Human Leukocyte Antigens (HLA) Allele Testing

Humana members may be eligible under the Plan for **HLA-A typing** when the following criteria are met^{110,138,150,187,219}:

- 18 years of age or older; **AND**
- Individual diagnosed with unresectable or metastatic synovial sarcoma; **AND**
- Testing performed prior to initiation of treatment with afamitresgene autoleucel (Tecelra)

Humana members may be eligible under the Plan for **HLA-A 02:01** testing when the following criteria are met:

- Individual diagnosed with unresectable or metastatic uveal melanoma; **AND**
- Testing performed prior to initiation of treatment with tebentafusp-tebn (Kimmtrak)

MAGE-A4 IHC Testing

Humana members may be eligible under the Plan for **MAGE-A4 IHC testing** when the following criteria are met^{138,187,198,219}:

- 18 years of age or older; **AND**
- Individual diagnosed with unresectable or metastatic synovial sarcoma; **AND**
- Testing performed prior to initiation of treatment with afamitresgene autoleucel (Tecelra)

MET Gene Test

Humana members may be eligible under the Plan for **MET gene testing** when the following criteria are met:

- Individual diagnosed with metastatic NSCLC; **AND**
- Testing performed prior to initiation of treatment with capmatinib (Tabrecta) or tepotinib (Tepmetko)

Microsatellite Instability and/or Mismatch Repair Testing

Humana members may be eligible under the Plan for **microsatellite instability (MSI) and/or mismatch repair deficient/ proficient testing (dMMR/pMMR)** when the following criteria are met:

- Individual diagnosed with an unresectable or metastatic [solid tumor](#)* that has progressed on prior therapy with no alternatives; **AND**

- Testing performed prior to initiation of treatment with dostarlimab-gxly (Jemperli); **OR**
- Testing performed prior to initiation of treatment with pembrolizumab (Keytruda), excluding pediatric patients with central nervous system cancers

For information regarding coverage determination/limitations for **MSI/MMR testing in Lynch syndrome**, please refer to [Genetic Testing for Hereditary Colorectal and Uterine Cancer](#) Medical Coverage Policy.

NTRK Test

Humana members may be eligible under the Plan for **NTRK1, NTRK2 and NTRK3 gene testing (8119181194)** when the following criteria are met:

- Individual diagnosed with a solid tumor that is either:
 - Advanced or metastatic; **OR**
 - Not a candidate for surgical resection; **AND**
- No alternative systemic therapy options; **AND**
- Testing performed prior to initiation of treatment with entrectinib (Rozlytrek) or larotrectinib (Vitrakvi)

PD-L1 TESTING

Humana members may be eligible under the Plan for **PD-L1 testing** when the following criteria are met:

Breast Cancer

- Individual diagnosed with locally recurrent unresectable or metastatic triple negative breast cancer; **AND**
- Testing performed using an FDA-approved test (**PD-L1 IHC 22C3 pharmDx**) prior to initiation of treatment with pembrolizumab (Keytruda)

Cervical Cancer

- Individual diagnosed with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy; **AND**
- Testing performed using an FDA-approved test (**PD-L1 IHC 22C3 pharmDx**) prior to initiation of treatment with pembrolizumab (Keytruda)

Esophageal Cancer

- Individual diagnosed with locally advanced or metastatic squamous cell carcinoma of the esophagus;
AND

- Testing performed using an FDA-approved test (**PD-L1 IHC 22C3 pharmDx**) prior to initiation of treatment with pembrolizumab (Keytruda)

Head and Neck

- Individual diagnosed with recurrent, unresectable or metastatic head and neck squamous cell carcinoma; **AND**
- Testing performed using an FDA-approved test (**PD-L1 IHC 22C3 pharmDx**) prior to initiation of treatment with pembrolizumab (Keytruda)

NSCLC

- Individual diagnosed with NSCLC; **AND**
 - Individual is post complete surgical resection and adjuvant platinum-based chemotherapy; **AND**
 - Testing performed using an FDA-approved test (**VENTANA PD-L1 Assay**) prior to initiation of **adjuvant** treatment with atezolizumab (Tecentriq); **OR**
- Individual diagnosed with advanced or metastatic NSCLC; **AND** any of the following:
 - Testing performed using an FDA-approved test (**PD-L1 IHC 22C3 pharmDx**) prior to initiation of treatment with cemiplimab-rwlc (Libtayo) or pembrolizumab (Keytruda); **OR**
 - Testing performed using an FDA-approved test (**PD-L1 IHC 28-8 pharmDx**) prior to initiation of treatment with ipilimumab (Yervoy) and nivolumab (Opdivo); **OR**
 - Testing performed using an FDA-approved test (**VENTANA PD-L1 Assay**) prior to initiation of treatment with atezolizumab (Tecentriq)

PIK3CA Gene Test

Humana members may be eligible under the Plan for **PIK3CA gene testing** when the following criteria are met:

- Individual diagnosed with metastatic breast cancer or breast cancer that has advanced on or after endocrine-based therapy; **AND**
- *HR*-positive and *HER2*-negative breast cancer; **AND**
- Testing performed using an FDA-approved test (**Therascreen PIK3CA RGQ PCR Kit [0155U]**) prior to initiation of treatment with alpelisib (Piqray) and fulvestrant (Faslodex)

PIK3CA/AKT1/PTEN Testing

Humana members may be eligible under the Plan for **PIK3CA/AKT1/PTEN testing** when the following criteria are met:

- Individual diagnosed with *HR*-positive, *HER2*-negative breast cancer that is locally advanced or metastatic; **AND**
- Individual has progressed on at least one prior endocrine-based therapy and has been treated in the metastatic setting or reoccurred within 12 months of completing adjuvant therapy; **AND**
- Testing performed using an FDA-approved test (**FoundationOne CDx [0037U]**) prior to initiation of treatment with capivasertib (Truqap)

RAS MUTATION ASSAY

Humana members may be eligible under the Plan for **RAS (KRAS and NRAS) mutation assay (eg, cobas KRAS Mutation Test)** when the following criteria are met:

Colon Cancer

- Individual diagnosed with CRC; **AND**
- Testing performed prior to the initiation of anti-*EGFR* antibody therapies cetuximab (Erbix) or panitumumab (Vectibix)

NSCLC

- Individual diagnosed with advanced or metastatic NSCLC; **AND**
- Disease progression on prior therapy; **AND**
- Testing performed prior to initiation of treatment with adagrasib (Krazati) or sotorasib (Lumakras)

RET Mutation Assay

Humana members may be eligible under the Plan for **RET mutation assay** when the following criteria are met:

- Individual diagnosed with metastatic NSCLC; **AND**
 - Testing performed prior to the initiation of treatment with pralsetinib (Gavreto) or selpercatinib (Retevmo); **OR**
- Individual diagnosed with advanced or metastatic solid tumors that progressed on prior systemic treatment or has no satisfactory alternative treatment options; **AND**
 - Testing performed prior to the initiation of treatment with selpercatinib (Retevmo)

ROS1 Proto-Oncogene Receptor Tyrosine Kinase Rearrangements

Humana members may be eligible under the Plan for **ROS1 proto-oncogene receptor tyrosine kinase rearrangement testing** when the following criteria are met:

- Individual diagnosed with locally advanced, recurrent or metastatic NSCLC; **AND**
- Testing performed prior to initiation of treatment with crizotinib (Xalkori), entrectinib (Rozlytrek), lorlatinib (Lorbrena) or repotrectinib (Augtyro)

Tumor Mutation Burden Test

Humana members may be eligible under the Plan for **tumor mutation burden (TMB) testing** when the following criteria are met:

- Individual diagnosed with metastatic or unresectable solid tumor (excluding pediatric individuals with central nervous system cancers) that has progressed on prior therapy with no alternatives; **AND**
- Testing performed prior to initiation of treatment with pembrolizumab (Keytruda)

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for **pharmacogenomics and companion diagnostics testing** for any indications other than those listed above including, but may not be limited to:

- *BTK* gene analysis (eg, chronic lymphocytic leukemia [81233]); **OR**
- Diagnosis for which pharmacologic therapy is not indicated and the drug(s) under consideration are not indicated for the treatment of the individual's diagnosis; **OR**
- Dihydropyrimidine dehydrogenase (DPYD) (81232), TYMS (81346) gene testing (eg, TheraGuide 5-FU) to predict response to fluorouracil or capecitabine (Xeloda) chemotherapy (excluding DPYD testing in instances of signs and symptoms of severe toxicity); **OR**
- Diseases for which the individual is not currently seeking treatment; **OR**
- *ERCC1* genetic testing to predict benefit from adjuvant platinum-based chemotherapy (eg, carboplatin [Paraplatin], cisplatin [Platinol], oxaliplatin [Eloxatin]); **OR**
- Evaluation of DNA conformational structures in the immune cells to assess the likelihood of response to immune checkpoint inhibitor (ICI) therapy targeting PD-L1 (eg, Episwitch CiRT [0332U]); **OR**
- *FGFR2/FGFR3* testing for any indications other than those listed above; **OR**
- HRD testing for any indication other than those listed above; **OR**
- MET testing for any indication other than those listed above; **OR**
- Multigene panels unless **ALL** genes in the panel meet disease- or gene-specific criteria (refer to Coverage Determination section). Examples include, but may not be limited to:
 - Targeted genomic sequence analysis panel, of 5-50 genes for solid organ neoplasm (81445); **OR**
 - Targeted genomic sequence analysis panel of 51 or more genes for solid organ or hematolymphoid neoplasm (81455) (eg, Tempus xT [0473U]); **OR**
- *PIK3CA* gene testing for any indication other than those listed above; **OR**
- *PLCG2* gene analysis (eg, chronic lymphocytic leukemia [81320]); **OR**
- *RAS* mutation testing for any indication other than those listed above; **OR**
- Reverse phase protein array, a semiquantitative analysis of 32 phosphoproteins and protein analytes (eg, Theralink [0249U]); **OR**

- Targeted KRAS and NRAS gene analysis formalin-fixed paraffin-embedded tissue (eg, Praxis extended RAS panel [0111U])

These are considered experimental/investigational as they are not identified as widely used and generally accepted for the proposed uses as reported in nationally recognized peer-reviewed medical literature published in the English language.

Humana members may **NOT** be eligible under the Plan for the following **pharmacogenomics and companion diagnostics testing**:

- UGT1A1* molecular assay to predict dosing of Camptosar (irinotecan) in the treatment of colorectal and lung cancers (81350)

This is considered not medically necessary as defined in the member's individual certificate. Please refer to the member's individual certificate for the specific definition.

Humana members may **NOT** be eligible under the Plan for **FoundationOne CDx (0037U)** for any indications other than those listed above. Humana considers FoundationOne CDx not medically necessary for assessing candidacy of an individual in other cancers since there is no proven advantage of the FoundationOne CDx gene panel over targeted gene testing or small targeted panels.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis	
81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis	
81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis	
81194	NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis	

81232	DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)	Not Covered if used to report any test outlined in Coverage Limitations section
81233	BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)	Not Covered

81236	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence	
81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)	
81275	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)	Not Covered if used to report any test outlined in Coverage Limitations section
81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)	Not Covered if used to report any test outlined in Coverage Limitations Section
81301	Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed	
81309	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)	
81320	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)	Not Covered
81346	TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)	Not Covered

81350	UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, drug metabolism, hereditary unconjugated hyperbilirubinemia [Gilbert syndrome]) gene analysis, common variants (eg, *28, *36, *37)	Not Covered
81378	HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLA-A, -B, -C, and -DRB1	
81379	HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA-A, -B, and -C)	
81380	HLA Class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-A, -B, or -C), each	

81381	HLA Class I typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, B*57:01P), each	
81400	MOLECULAR PATHOLOGY PROCEDURE LEVEL 1	Not Covered if used to report any test outlined in Coverage Limitations section
81401	MOLECULAR PATHOLOGY PROCEDURE LEVEL 2	
81403	MOLECULAR PATHOLOGY PROCEDURE LEVEL 4	
81404	MOLECULAR PATHOLOGY PROCEDURE LEVEL 5	
81445	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed	Not Covered if used to report any test outlined in Coverage Limitations section

81455	Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed	Not Covered if used to report any test outlined in Coverage Limitations section
81479	Unlisted molecular pathology procedure	Not Covered if used to report any test outlined in Coverage Limitations section
84999	Unlisted chemistry procedure	Not Covered if used to report any test outlined in Coverage Limitations section
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)	
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure	Not Covered if used to report any test outlined in Coverage Limitations section
88344	Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure	

88360	Morphometric analysis, tumor immunohistochemistry (eg, Her2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; manual	
0037U	Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	
0111U	Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue	Not Covered

0154U	Oncology (urothelial cancer), RNA, analysis by real-time RT-PCR of the FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3TACC3v3) utilizing formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as FGFR gene alteration status	
0155U	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y), utilizing formalin-fixed paraffin-embedded breast tumor tissue, reported as PIK3CA gene mutation status	
0172U	Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score	
0249U	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report	Not Covered
0332U	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint–inhibitor therapy	Not Covered
0471U	Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin-fixed paraffin-embedded (FFPE), predictive, identification of detected mutations	New Code Effective 07/01/2024
0473U	Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden	Not Covered New Code Effective 07/01/2024

CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American Society of Clinical Oncology (ASCO). Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. <https://www.asco.org>. Published April 19, 2022.
2. American Society of Clinical Oncology (ASCO). Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. <https://www.asco.org>. Published June 2022.
3. American Society of Clinical Oncology (ASCO). Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. <https://www.asco.org>. Published July 2021.
4. American Society of Clinical Oncology (ASCO). Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. <https://www.asco.org>. Published July 2021.
5. American Society of Clinical Oncology (ASCO). Germline testing in patients with breast cancer: ASCO Society of Surgical Oncology Guideline. <https://www.asco.org>. Published January 4, 2024.
6. American Society of Clinical Oncology (ASCO). Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology clinical practice guideline update. <https://www.asco.org>. Published February 2018. Updated March 20, 2018.
7. American Society of Clinical Oncology (ASCO). Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. <https://www.asco.org>. Published August 13, 2020. Updated September 23, 2022.

8. American Society of Clinical Oncology (ASCO). Somatic genomic testing in patients with metastatic or advanced cancer. <https://www.asco.org>. Published February 17, 2022.
9. American Society of Clinical Oncology (ASCO). Testing for *ESR1* mutations to guide therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline rapid recommendation update. <https://www.asco.org>. Published March 23, 2023.
10. American Society of Clinical Oncology (ASCO). Treatment of metastatic colorectal cancer: ASCO guideline. <https://www.asco.org>. Published October 17, 2022.
11. Association for Molecular Pathology (AMP). Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. <https://www.amp.org>. Published January 1, 2017.
12. Association for Molecular Pathology (AMP). Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <https://www.amp.org>. Published January 23, 2018.
13. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD). Next generation sequencing (NGS) (90.2). <https://www.cms.gov>. Published January 27, 2020.
14. Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC gene-drugs for DPYD. <https://www.cpic.com>. Published February 2020.
15. Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC gene-drugs for ERCC1. <https://www.cpic.com>. Published April 3, 2023.
16. Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC gene-drugs for UGT1A1. <https://www.cpic.com>. Updated June 1, 2022.
17. ClinicalKey. Clinical Overview. Bladder cancer. <https://www.clinicalkey.com>. Updated January 5, 2024.
18. ClinicalKey. Clinical Overview. Breast cancer in females. <https://www.clinicalkey.com>. Updated January 30, 2024.

19. ClinicalKey. Clinical Overview. Cervical cancer. <https://www.clinicalkey.com>. Updated April 25, 2023.
20. ClinicalKey. Clinical Overview. Cholangiocarcinoma. <https://www.clinicalkey.com>. Updated July 26, 2022.
21. ClinicalKey. Clinical Overview. Chronic lymphocytic leukemia. <https://www.clinicalkey.com>. Updated January 1, 2024.

Pharmacogenomics and Companion Diagnostics

Page: 17 of 30

22. ClinicalKey. Clinical Overview. Colorectal cancer. <https://www.clinicalkey.com>. Updated April 26, 2022.
23. ClinicalKey. Clinical Overview. Endometrial carcinoma. <https://www.clinicalkey.com>. Updated April 22, 2022.
24. ClinicalKey. Clinical Overview. Esophageal cancer. <https://www.clinicalkey.com>. Updated April 13, 2023.
25. ClinicalKey. Clinical Overview. Follicular lymphoma. <https://www.clinicalkey.com>. Updated March 9, 2022.
26. ClinicalKey. Clinical Overview. Lung cancer (non-small cell). <https://www.clinicalkey.com>. Updated May 5, 2023.
27. ClinicalKey. Clinical Overview. Ovarian cancer. <https://www.clinicalkey.com>. Updated January 31, 2023.
28. ClinicalKey. Clinical Overview. Pancreatic cancer. <https://www.clinicalkey.com>. Updated April 27, 2023.
29. College of American Pathologists (CAP). Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy statements and strengths of recommendations. <https://www.cap.org>. Published August 2022.
30. College of American Pathologists (CAP). Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <https://www.cap.org>. Published May 2017.

31. Drilon A, Laetsch T, Kummar S et al. Efficacy of larotrectinib in TRK fusion positive cancers in adults and children. *N Engl J Med*. 2018;378:731-739.
32. Dugay F, Llamas-Gutierrez, Gournay, Marjory, et al. Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/ PIK3CA/ALK alterations. *Oncotarget*. 2017;8(32):53336-53351.
33. ECRI Institute. ECRIgene Genetic Test Assessment. cobas EZH2 mutation test (Roche Molecular Diagnostics) to determine eligibility for Tazemetostat (tazverik) therapy for follicular lymphoma. <https://www.ecri.org>. Published August 2020.
34. ECRI Institute. ECRIgene Genetic Test Assessment. MyChoice CDx (Myriad Genetics, Inc.) for determining eligibility for targeted treatment for ovarian cancer. <https://www.ecri.org>. Published October 5, 2020.

Pharmacogenomics and Companion Diagnostics

Page: 18 of 30

35. ECRI Institute. ECRIgene Genetic Test Assessment. Paradigm cancer diagnostic PCDx test (Paradigm Diagnostics, Inc.) for guiding targeted therapy for solid tumors. <https://www.ecri.org>. Published March 9, 2021.
36. ECRI Institute. ECRIgene Genetic Test Assessment. Praxis extended RAS panel (Illumina, Inc) to determine eligibility for panitumumab (Vectibix) to treat colorectal cancer. <https://www.ecri.org>. Published October 2020.
37. ECRI Institute. ECRIgene Genetic Test Assessment. Tempus xT (Tempus) for guiding targeted therapy for solid tumor cancers. <https://www.ecri.org>. Published November 2022.
38. ECRI Institute. ECRIgene Genetic Test Assessment. Ventana FOLR1 (FOLR1-2.1) RxDx Assay (Ventana Medical Systems, Inc.) to determine eligibility for mirvetuximab soravtansine (Elahere) for treating epithelial ovarian cancer. <https://www.ecri.org>. Published July 25, 2023.
39. ECRI Institute. ECRIgene Genetic Test Assessment. Ventana PD-L1 (SP142) Assay (Ventana Medical Systems Inc. A Roche Group Co) to determine eligibility for Tecentriq (Atezolizumab) to treat NSCLC. <https://www.ecri.org>. Published October 27, 2020.
40. ECRI Institute. ECRIgene Genetic Test Product Brief. BRACAnalysis CDx (Myriad Genetics, Inc.) for determining eligibility for PARP inhibitor treatment for ovarian cancer. <https://www.ecri.org>. Published May 24, 2018. Updated December 13, 2022.

41. ECRI Institute. ECRIgene Genetic Test Product Brief. cobas KRAS (Roche Molecular Systems, Inc.) for determining eligibility for Erbitux (Cetuximab) or Vectibix (Panitumumab) treatment for colorectal cancer. <https://www.ecri.org>. Published July 2017.
42. ECRI Institute. ECRIgene Genetic Test Product Brief. FoundationOne CDx (Foundation Medicine, Inc.) genomic profiling test for guiding targeted therapy for cancer. <https://www.ecri.org>. Published August 29, 2018. Updated September 2019.
43. ECRI Institute. ECRIgene Genetic Test Product Brief. Therascreen FGFR RGQ RT-PCR kit (Qiagen GmbH) for determining eligibility for erdafitinib (balversa) treatment for urothelial cancer. <https://www.ecri.org>. Published May 20, 2019.
44. ECRI Institute. ECRIgene Genetic Test Product Brief. Therascreen KRAS RGQ PCR kit (Qiagen N.V.) for determining eligibility for vectibix or erbitux treatment for colorectal cancer. <https://www.ecri.org>. Published July 1, 2016. Updated March 27, 2019.
45. ECRI Institute. ECRIgene Genetic Test Product Brief. Therascreen PIK3CA RGQ PCR kit (Qiagen GmbH) for determining eligibility for alpelisib (Piqray) treatment for breast cancer. <https://www.ecri.org>. Updated June 13, 2019.
46. ECRI Institute. ECRIgene Genetic Test Product Brief. Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems) for determining eligibility for alectinib, xalkori, or zykadia for treating non-small cell lung cancer. <https://www.ecri.org>. Published August 1, 2018.

Pharmacogenomics and Companion Diagnostics

Page: 19 of 30

47. Farago A, Taylor M, Doebele R, et al. Clinicopathologic features of non-small-cell lung cancer harboring an *NTRK* gene fusion. *JCO Precis Oncol*. 2018;10.120.
48. Febbo P, Ladanyi M, Aldape K, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. *J Natl Compr Canc Netw*. 2011;9:S-1-S-33.
49. Garon E, Rizvi N, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372:2018-2028.
50. Hayes, Inc. Emerging Technology Report. Balversa (erdafitinib) for urothelial carcinoma. <https://evidence.hayesinc.com>. Published August 19, 2019.
51. Hayes, Inc. Emerging Technology Report. Pemazyre (pemigatinib). <https://evidence.hayesinc.com>. Published April 21, 2020.

52. Hayes, Inc. Emerging Technology Report. Rozlytrek (entrectinib). <https://evidence.hayesinc.com>. Published August 19, 2019. Updated September 11, 2020.
53. Hayes, Inc. Emerging Technology Report. Vitrakvi (larotrectinib). <https://evidence.hayesinc.com>. Published November 27, 2018. Updated May 8, 2020.
54. Hayes, Inc. Genetic Test Evaluation (GTE) Report. Anaplastic lymphoma kinase (ALK) gene rearrangement testing in non-small cell lung cancer (NSCLC). <https://evidence.hayesinc.com>. Published July 26, 2012. Updated July 9, 2014.
55. Hayes, Inc. Genetic Test Evaluation (GTE) Report. ERCC1 expression analysis non-small cell lung cancer (NSCLC). <https://evidence.hayesinc.com>. Published January 17, 2014. Updated January 8, 2015.
56. Hayes, Inc. Genetic Test Evaluation (GTE) Report. KRAS sequence variant analysis for predicting response to colorectal cancer drug therapy. <https://evidence.hayesinc.com>. Published December 2011. Updated May 27, 2015.
57. Hayes, Inc. Genetic Test Evaluation (GTE) Report. KRAS sequence variant analysis for predicting response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of non-small cell lung cancer (NSCLC). <https://evidence.hayesinc.com>. Published April 26, 2012. Updated April 13, 2015.
58. Hayes, Inc. Genetic Test Evaluation (GTE) Report. Neuroblastoma RAS viral oncogene (NRAS) testing to predict treatment response in colorectal cancer. <https://evidence.hayesinc.com>. Published February 5, 2012. Updated January 19, 2019.
59. Hayes, Inc. Genetic Test Evaluation (GTE) Report. TheraGuide 5-FU (Myriad Genetic Laboratories Inc.) for predicting toxicity to 5-fluorouracil (5-FU)/capecitabine-based chemotherapy. <https://evidence.hayesinc.com>. Published May 5, 2009. Updated May 14, 2013.

Pharmacogenomics and Companion Diagnostics

Page: 20 of 30

60. Hayes, Inc. Genetic Test Evaluation (GTE) Report. UGT1A1 sequence variant testing for predicting response to Irinotecan therapy in colorectal cancer. <https://evidence.hayesinc.com>. Updated January 2014.
61. Hayes, Inc. Genetic Testing Evaluation (GTE) Synopsis. ROS1 gene rearrangements in NSCLC. <https://evidence.hayesinc.com>. Published February 2015. Updated September 12, 2018.

62. Hayes, Inc. Molecular Test Assessment. FoundationOne CDx (Foundation Medicine Inc.) for the intended use as a broad molecular profiling tool. <https://evidence.hayesinc.com>. Published August 29, 2018. Updated May 17, 2023.
63. Hayes, Inc. Precision Medicine Insights. Comprehensive molecular profiling test(s) for solid tumors intended to be used as broad molecular profiling tool to assigned matched therapy. <https://evidence.hayesinc.com>. Published January 11, 2022. Updated April 26, 2022.
64. Hayes, Inc. Precision Medicine Insights. MyChoice CDx (Myriad Genetics Inc.). <https://evidence.hayesinc.com>. Published October 14, 2022.
65. Hayes, Inc. Precision Medicine Research Brief. Tempus xT (Tempus Lab Inc.). <https://evidence.hayesinc.com>. Published October 13, 2023.
66. Kummar S, Lassen U. TRK inhibition: a new tumor-agnostic treatment strategy. *U.N. Targ Oncol.* 2018;13:545-556.
67. Liu B, Song Y, Liu, Delong. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. *J Hematol Oncol.* 2017;10:174.
68. Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. *Ann Oncol.* 2022;33(9):929-938.
69. National Cancer Institute (NCI). Bile duct cancer (cholangiocarcinoma) treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated December 22, 2023.
70. National Cancer Institute (NCI). Bladder cancer treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated January 18, 2023.
71. National Cancer Institute (NCI). Cervical cancer treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated June 2, 2023.
72. National Cancer Institute (NCI). Colorectal cancer treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated January 20, 2023.
73. National Cancer Institute (NCI). Esophageal cancer treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated July 15, 2022.

74. National Cancer Institute (NCI). Head and neck cancer treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated March 11, 2023.
75. National Cancer Institute (NCI). Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated March 14, 2023.
76. National Cancer Institute (NCI). Pancreatic treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated October 5, 2023.
77. National Cancer Institute (NCI). Thyroid cancer treatment (PDQ) – health professional version. <https://www.cancer.gov>. Updated February 18, 2022.
78. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. ALK receptor tyrosine kinase. <https://www.ncbi.nlm.nih.gov>. Updated April 24, 2022.
79. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Dihydropyrimidine dehydrogenase. <https://www.ncbi.nlm.nih.gov>. Updated October 10, 2023.
80. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. ERCC excision repair 1, endonuclease non-catalytic subunit. <https://www.ncbi.nlm.nih.gov>. Updated May 1, 2023.
81. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. FoundationOne CDx. <https://www.ncbi.nlm.nih.gov>. Updated August 7, 2022.
82. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. KRAS protooncogene, GTPase. <https://www.ncbi.nlm.nih.gov>. Updated May 8, 2022.
83. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. MET proto-oncogene, receptor tyrosine kinase. <https://www.ncbi.nlm.nih.gov>. Updated April 24, 2022.
84. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. NTRK neurotrophic receptor tyrosine kinase. <https://www.ncbi.nlm.nih.gov>. Updated February 5, 2023.
85. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. PD-L1 22C3 IHC with combined positive score (CPS) interpretation, pembrolizumab. <https://www.ncbi.nlm.nih.gov>. Updated July 21, 2023.
86. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. RET proto-oncogene. <https://www.ncbi.nlm.nih.gov>. Updated April 24, 2022.

87. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. ROS proto-oncogene 1, receptor tyrosine kinase. <https://www.ncbi.nlm.nih.gov>. Updated April 24, 2022.
88. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Tempus xT. <https://www.ncbi.nlm.nih.gov>. Updated September 1, 2023.

89. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. UGT1A1. <https://www.ncbi.nlm.nih.gov>. Updated October 10, 2023.
90. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium: ALK, BRCA1, BRCA2, BTK, EZH2 FGFR, FLT3, FOLR1, HRD, KRAS, MSI, PD-L1, PIK3CA, PLCG2, MET, NTRK, RET, ROS1, TMB. <https://www.nccn.org>. Published 2024.
91. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bcell lymphoma. <https://www.nccn.org>. Updated October 10, 2023.
92. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Biliary tract cancers. <https://www.nccn.org>. Updated November 8, 2023.
93. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder cancer. <https://www.nccn.org>. Updated January 30, 2024.
94. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. <https://www.nccn.org>. Updated January 25, 2024.
95. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. <https://www.nccn.org>. Updated April 28, 2023.
96. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma. <https://www.nccn.org>. Updated November 3, 2024.
97. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon cancer. <https://www.nccn.org>. Updated January 29, 2024.
98. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. <https://www.nccn.org>. Updated March 10, 2023.
99. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Head and neck cancers. <https://www.nccn.org>. Updated May 15, 2023.
100. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary cancer. <https://www.nccn.org>. Updated January 13, 2023.
101. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Melanoma: uveal. <https://www.nccn.org>. Updated May 4, 2023.
102. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Nonsmall cell lung cancer. <https://www.nccn.org>. Updated December 21, 2023.

103. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer. <https://www.nccn.org>. Updated January 17, 2024.
104. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Pancreatic cancer. <https://www.nccn.org>. Updated December 13, 2023.
105. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. <https://www.nccn.org>. Updated January 10, 2022.
106. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Rectal cancer. <https://www.nccn.org>. Updated September 10, 2021.
107. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine neoplasms. <https://www.nccn.org>. Updated April 28, 2023.
108. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med*. 2019;381:2416-2428.
109. Rebutzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer. *Int J Mol Sci*. 2021;22(5):2625.
110. Rosenbaum E, Seier K, Bandlamudi C, et al. HLA genotyping in synovial sarcoma: identifying HLA-A*02 and its association with clinical outcome. *Clin Cancer Res*. 2020;26(20):5448-5455.
111. Rossi G, Jocollé G, Conti A, et al. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. *Dove Press Journal*. 2017;8:45-55.
112. Sha D, Jin Z, Budczies J, et al. Tumor mutational burden as a predictive biomarker in solid tumors. *Cancer Discov*. 2020;10(12):1808-1825. doi:10.1158/2159-8290.CD-20-0522.
113. Tutt A, Garber J, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *N Engl J Med*. 2021;384:2394.
114. UpToDate, Inc. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. <https://www.uptodate.com>. Updated April 2023.
115. UpToDate, Inc. Chemotherapy associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation. <https://www.uptodate.com>. Updated October 2023.
116. UpToDate, Inc. Dosing of anticancer agents in adults. <https://www.uptodate.com>. Updated October 2023.

117. UpToDate, Inc. ER/PR negative, HER2-negative (triple-negative) breast cancer. <https://www.uptodate.com>. Updated July 2023.
118. UpToDate, Inc. Familial risk factors for pancreatic cancer and screening of high-risk patients. <https://www.uptodate.com>. Updated December 2022.
119. UpToDate, Inc. Gene therapy and other investigational approaches for hemophilia. <https://www.uptodate.com>. Updated November 2, 2023.
120. UpToDate, Inc. Initial management of advanced non-small cell lung cancer lacking a driver mutation. <https://www.uptodate.com>. Updated July 2023.
121. UpToDate, Inc. Initial systemic chemotherapy for metastatic exocrine pancreatic cancer. <https://www.uptodate.com>. Updated December 2023.
122. UpToDate, Inc. Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer. <https://www.uptodate.com>. Updated July 2023.
123. UpToDate, Inc. Malignant salivary gland tumors: treatment of recurrent and metastatic disease. <https://www.uptodate.com>. Updated January 2023.
124. UpToDate, Inc. Management of advanced non-small cell lung cancer lacking a driver mutation: immunotherapy. <https://www.uptodate.com>. Updated July 2022.
125. UpToDate, Inc. Management of ovarian cancer associated with BRCA and other genetic mutations. <https://www.uptodate.com>. Updated December 2023.
126. UpToDate, Inc. Management of recurrent high-grade gliomas. **Error! Hyperlink reference not valid.** Updated January 2023.
127. UpToDate, Inc. Management of recurrent or metastatic cervical cancer. **Error! Hyperlink reference not valid.** July 2023.
128. UpToDate, Inc. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: platinum-resistant disease. <https://www.uptodate.com>. Updated January 2024.
129. UpToDate, Inc. Metastatic uveal melanoma. <https://www.uptodate.com>. Updated April 2023.
130. UpToDate, Inc. Methods to overcome radiation resistance in head and neck cancer. <https://www.uptodate.com>. Updated April 2023.
131. UpToDate, Inc. Molecular genetics of colorectal cancer. <https://www.uptodate.com>. Updated March 2023.

132. UpToDate, Inc. Molecular pathogenesis of exocrine pancreatic cancer. <https://www.uptodate.com>. Updated January 2022.
133. UpToDate, Inc. Overview of pharmacogenomics. <https://www.uptodate.com>. Updated October 2023.
134. UpToDate, Inc. Overview of the approach to metastatic breast cancer. <https://www.uptodate.com>. Updated December 2023.
135. UpToDate, Inc. Overview of the initial treatment of advanced non-small cell lung cancer. <https://www.uptodate.com>. Updated April 2023.
136. UpToDate, Inc. Pathology and prognostic determinants of colorectal cancer. <https://www.uptodate.com>. Updated March 2023.
137. UpToDate, Inc. Personalized genotype-directed therapy for advanced non-small cell lung cancer. <https://www.uptodate.com>. Updated March 2023.
138. UpToDate, Inc. Second and later lines of therapy for metastatic soft tissue sarcoma. <https://www.uptodate.com>. Updated August 20, 2024.
139. UpToDate, Inc. Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer. <https://www.uptodate.com>. Updated December 2022.
140. UpToDate, Inc. Systemic therapy for advanced cholangiocarcinoma. <https://www.uptodate.com>. Updated January 2024.
141. UpToDate, Inc. Systemic treatment of metastatic soft tissue sarcoma. <https://www.uptodate.com>. Updated January 2023.
142. UpToDate, Inc. Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors. <https://www.uptodate.com>. Updated October 2023.
143. UpToDate, Inc. Treatment for hormone receptor-positive, HER2-negative advanced breast cancer. <https://www.uptodate.com>. Updated July 2023.
144. UpToDate, Inc. Treatment of metastatic and recurrent head and neck cancer. <https://www.uptodate.com>. Updated July 2023.
145. UpToDate, Inc. Treatment of metastatic endometrial cancer. <https://www.uptodate.com>. Updated April 2023.

146. UpToDate, Inc. Treatment of metastatic urothelial cancer of the bladder and urinary tract. <https://www.uptodate.com>. Updated January 2024.
 147. UpToDate, Inc. Treatment of relapsed or refractory chronic lymphocytic leukemia. <https://www.uptodate.com>. Updated December 2023.
 148. UpToDate, Inc. Treatment of relapsed or refractory follicular lymphoma. <https://www.uptodate.com>. Updated October 2023.
 149. UpToDate, Inc. TRK fusion-positive cancers and TRK inhibitor therapy. <https://www.uptodate.com>. Updated January 2024.
-

150. US Food & Drug Administration (FDA). 510(k) Approval. SeCore CDx HLA Sequencing System. <https://www.fda.gov>. Published August 1, 2024.
151. US Food & Drug Administration (FDA). 510(k) substantial equivalence determination decision summary: Invader assay UGT1A1. <https://www.fda.gov>. Published 2008.
152. US Food & Drug Administration (FDA). Premarket Approval (PMA). MAGE-A4 IHC 1F9 pharmDx. <https://www.fda.gov>. Published August 1, 2024.
153. US Food & Drug Administration (FDA). De novo summary: SeCore CDx HLA sequencing system. <https://www.fda.gov>. Published November 28, 2022.
154. US Food & Drug Administration (FDA). Full prescribing information: Alecensa (alectinib). <https://www.fda.gov>. Published January 2021. Updated September 2021.
155. US Food & Drug Administration (FDA). Full prescribing information: Alunbrig (brigatinib). <https://www.fda.gov>. Published April 28, 2017. Updated February 2022.
156. Food & Drug Administration (FDA). Full prescribing information: Augtyro (repotrectinib). <https://www.fda.gov>. Published November 2023.
157. US Food & Drug Administration (FDA). Full prescribing information: Avastin (bevacizumab). <https://www.fda.gov>. Published December 2020. Updated September 18, 2022.
158. US Food & Drug Administration (FDA). Full prescribing information: Balversa (erdafitinib). <https://www.fda.gov>. Published April 2019. Updated January 19, 2024.
159. US Food & Drug Administration (FDA). Full prescribing information: Camptosar (Irinotecan). <https://www.fda.gov>. Published December 19, 2014. Updated January 2022.
160. US Food & Drug Administration (FDA). Full prescribing information: Elahere (mirvetuximab soravtansine-gynx). <https://www.fda.gov>. Published November 2022.
161. US Food & Drug Administration (FDA). Full prescribing information: Eloxatin (oxaliplatin). <https://www.fda.gov>. Updated March 2020.

<https://www.fda.gov>.

162. US Food & Drug Administration (FDA). Full prescribing information: Erbitux (cetuximab). <https://www.fda.gov>. Updated September 2021.
163. US Food & Drug Administration (FDA). Full prescribing information: Faslodex (fulvestrant). <https://www.fda.gov>. Updated April 2020.
164. US Food & Drug Administration (FDA). Full prescribing information: Fluorouracil. Published July 2016.
165. US Food & Drug Administration (FDA). Full prescribing information: Gavreto (pralsetinib). <https://www.fda.gov>. Updated September 2022.
166. US Food & Drug Administration (FDA). Full prescribing information: Jemperli (dostarlimab-gxly)). <https://www.fda.gov>. Updated July 2023.
167. US Food & Drug Administration (FDA). Full prescribing information: Keytruda (pembrolizumab). <https://www.fda.gov>. Updated November 2023.
168. US Food & Drug Administration (FDA). Full prescribing information: Kimmtrak (tebentafusp-tebn). <https://www.fda.gov>. Published November 2022.
169. US Food & Drug Administration (FDA). Full prescribing information: Krazati (adagrasib). <https://www.fda.gov>. Published December 2022.
170. US Food & Drug Administration (FDA). Full prescribing information: Libtayo (cemiplimab-rwlc). <https://www.fda.gov>. Updated April 2023.
171. US Food & Drug Administration (FDA). Full prescribing information: Lorbreña (lorlatinib). <https://www.fda.gov>. Updated March 2021.
172. US Food & Drug Administration (FDA). Full prescribing information: Lumakras (sotorasib). <https://www.fda.gov>. Updated January 2023.
173. US Food & Drug Administration (FDA). Full prescribing information: Lynparza (olaparib). <https://www.fda.gov>. Updated November 2023.

174. US Food & Drug Administration (FDA). Full prescribing information: Lytgobi (futibatinib). <https://www.fda.gov>. Updated September 2022.
175. US Food & Drug Administration (FDA). Full prescribing information: Ogivri (trastuzumab-dkst). <https://www.fda.gov>. Updated April 17, 2019.
176. US Food & Drug Administration (FDA). Full prescribing information: Opdivo (nivolumab). <https://www.fda.gov>. Updated February 2023.
177. US Food & Drug Administration (FDA). Full prescribing information: Paraplatin (carboplatin). <https://www.fda.gov>. Updated 2010.
178. US Food & Drug Administration (FDA). Full prescribing information: Pemazyre (pemigatinib). <https://www.fda.gov>. Updated August 2022.
179. US Food & Drug Administration (FDA). Full prescribing information: Piqray (alpelisib). Updated November 2022.
180. US Food & Drug Administration (FDA). Full prescribing information: Platinol (cisplatin). <https://www.fda.gov>. Published February 2019.
181. US Food & Drug Administration (FDA). Full prescribing information: Retevmo (selpercatinib). <https://www.fda.gov>. Updated September 2022.
182. US Food & Drug Administration (FDA). Full prescribing information: Roctavian (valoctocogene roxaparvovec-rvox). <https://www.fda.gov>. Updated June 2023.
183. US Food & Drug Administration (FDA). Full prescribing information: Rozlytrek (entrectinib). <https://www.fda.gov>. Updated January 2024.
184. US Food & Drug Administration (FDA). Full prescribing information: Rubraca (rucaparib). <https://www.fda.gov>. Updated December 2022.
185. US Food & Drug Administration (FDA). Full prescribing information: Tabrecta (capmatinib).

- <https://www.fda.gov>. Updated March 2023.
186. US Food & Drug Administration (FDA). Full prescribing information: Talzenna (talazoparib tosylate). <https://www.fda.gov>. Updated June 2023.
187. US Food & Drug Administration (FDA). Full prescribing information: Tazverik (tazemetostat). <https://www.fda.gov>. Updated June 18, 2020.
188. US Food & Drug Administration (FDA). Full prescribing information: Tecelra (afamitresgene autoleucel). <https://www.fda.gov>. Published August 2024.
189. US Food & Drug Administration (FDA). Full prescribing information: Tecentriq (atezolizumab). <https://www.fda.gov>. Updated May 2023.
190. US Food & Drug Administration (FDA). Full prescribing information: Tepmetko (tepotinib). <https://www.fda.gov>. Updated March 2023.
191. US Food & Drug Administration (FDA). Full prescribing information: Trucap (capivasertib). <https://www.fda.gov>. Published November 2023.
192. US Food & Drug Administration (FDA). Full prescribing information: Truseltiq (infigratinib). <https://www.fda.gov>. Updated May 2021.
193. US Food & Drug Administration (FDA). Full prescribing information: Vectibix (panitumumab). <https://www.fda.gov>. Updated August 2021.
194. US Food & Drug Administration (FDA). Full prescribing information: Vittrakvi (larotrectinib). Updated November 2022.
195. US Food & Drug Administration (FDA). Full prescribing information: Xalkori (crizotinib). <https://www.fda.gov>. Updated July 2022.
196. US Food & Drug Administration (FDA). Full prescribing information: Xeloda (capecitabine). <https://www.fda.gov>. Updated December 2022.

197. US Food & Drug Administration (FDA). Full prescribing information: Yervoy (ipilimumab). <https://www.fda.gov>. Updated February 2023.
198. US Food & Drug Administration (FDA). Premarket Approval. AAV5 DetectCDx. <https://www.fda.gov>. Published June 29, 2023.
199. US Food & Drug Administration (FDA). Premarket Approval. MAGe-A4 IHC 1F9 pharmDx. <https://www.fda.gov>. Published August 1, 2024.
200. US Food & Drug Administration (FDA). Full prescribing information: Zykadia (ceritinib). <https://www.fda.gov>. Updated October 2021.
201. US Food & Drug Administration (FDA). List of cleared or approved companion diagnostic devices (in vitro and imaging tools). <https://www.fda.gov>. Updated December 21, 2023.
202. US Food & Drug Administration (FDA). Premarket approval. BRACAnalysis CDx. <https://www.fda.gov>. Published June 29, 2018. Updated May 19, 2020.
203. US Food & Drug Administration (FDA). Premarket approval. Cobas EZH2 mutation test. <https://www.fda.gov>. Published June 18, 2020.
204. US Food & Drug Administration (FDA). Premarket approval. Cobas KRAS mutation test. <https://www.fda.gov>. Published May 7, 2015. Updated September 2016.
205. US Food & Drug Administration (FDA). Premarket approval. FoundationFocus CDxBRCA. <https://www.fda.gov>. Published December 19, 2016.
206. US Food & Drug Administration (FDA). Premarket approval. FoundationOne CDx. <https://www.fda.gov>. Published June 2, 2017. Updated November 16, 2023.
207. US Food & Drug Administration (FDA). Premarket approval. MyChoice HRD CDx. <https://www.fda.gov>. Updated 2020.
208. US Food & Drug Administration (FDA). Premarket approval. Praxis Extended RAS Panel. <https://www.fda.gov>. Updated 2017.

209. US Food & Drug Administration (FDA). Premarket approval. PD-L1 IHC 22C3 PharmDx. Updated February 2021.

210. US Food & Drug Administration (FDA). Premarket approval. PD-L1 IHC 28-8 PharmDx. <https://www.fda.gov>. Updated May 2020.
211. US Food & Drug Administration (FDA). Premarket approval. Tempus xT. <https://www.fda.gov>. Updated 2023.
212. US Food & Drug Administration (FDA). Premarket approval. Therascreen FGFR RGQ PCR Kit. <https://www.fda.gov>. Updated 2019.
213. US Food & Drug Administration (FDA). Premarket approval. Therascreen KRAS RGQ PCR Kit. <https://www.fda.gov>. Updated 2022.
214. US Food & Drug Administration (FDA). Premarket approval. Therascreen PIK3CA RGQ PCR Kit. <https://www.fda.gov>. Updated 2019.
215. US Food & Drug Administration (FDA). Premarket approval. Ventana ALK (D5F3) CDx assay – P140025. <https://www.fda.gov>. Updated March 3, 2021.
216. US Food & Drug Administration (FDA). Premarket approval. Ventana FOLR1 (FOLR-2.1) RxDx Assay – P220006. <https://www.fda.gov>. Updated November 18, 2022.
217. US Food & Drug Administration (FDA). Premarket approval. Ventana MMR RxDx Panel – P200019. <https://www.fda.gov>. Updated June 16, 2022.
218. US Food & Drug Administration (FDA). Premarket approval. Ventana PD-L1 (SP263) Assay – P160046. <https://www.fda.gov>. Updated October 15, 2021.
219. US Food & Drug Administration (FDA). Premarket approval. Vysis ALK Break Apart Fish Probe Kit. <https://www.fda.gov>. Updated May 5, 2020.
220. Wang T, Navenot JM, Rafail S, et al. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A*02-eligible patients. *Mol Ther Methods Clin Dev.* 2024;32(2):101265.
221. Zhang C, Liu H, Ma B, et al. The impact of the expression level of intratumoral dihydropyrimidine dehydrogenase on chemotherapy sensitivity and survival of patients in gastric cancer: a metaanalysis. *Dis Markers.* 2017;2017:9202676.

Change Summary

01/25/2024 Update, Coverage Change. Updated Coding Information. 02/29/2024
Update, Coverage Change.

06/27/2024 Updated Coding Information.

09/26/2024 Update, Coverage Change.